ReviewMolecules (Basel, Switzerland)2014
Clinical application of microRNA testing in neuroendocrine tumors of the gastrointestinal tract.
Review in Molecules (Basel, Switzerland), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Toward Timely Diagnosis of Pancreatic Cancer: Revolutionizing Early Detection Through Genomics, Artificial Intelligence, and Noninvasive Biomarkers.Journal of gastroenterology and hepatology · 2026Review
- Dynamic nomogram for predicting the overall survival and cancer-specific survival of patients with gastrointestinal neuroendocrine tumor: a SEER-based retrospective cohort study and external validation.Frontiers in oncology · 2025Article
- Circulating non-coding RNA biomarkers of endocrine tumours.Nature reviews. Endocrinology · 2024Review
- Article
- Biochemical Markers for Neuroendocrine Tumors: Traditional Circulating Markers and Recent Development-A Comprehensive Review.Diagnostics (Basel, Switzerland) · 2024Review
- An Overview of Circulating Biomarkers in Neuroendocrine Neoplasms: A Clinical Guide.Diagnostics (Basel, Switzerland) · 2023Review
- Molecular biology of pancreatic neuroendocrine tumors: From mechanism to translation.Frontiers in oncology · 2022Review
- Perspectives on the diagnostic, predictive and prognostic markers of neuroendocrine neoplasms (Review).Experimental and therapeutic medicine · 2021Review
- The Role of miRNA in the Pathophysiology of Neuroendocrine Tumors.International journal of molecular sciences · 2021Review
- The Potential Role of Liquid Biopsies in Advancing the Understanding of Neuroendocrine Neoplasms.Journal of clinical medicine · 2021Review
- Serum Exosomes Derived from Irritable Bowel Syndrome Patient Increase Cell Permeability via Regulating miR-148b-5p/RGS2 Signaling in Human Colonic Epithelium Cells.Gastroenterology research and practice · 2021Article
- A Plasma Protein Biomarker Strategy for Detection of Small Intestinal Neuroendocrine Tumors.Neuroendocrinology · 2021Observational
- Dynamic Enhancement Pattern on CT for Predicting Pancreatic Neuroendocrine Neoplasms with Low PAX6 Expression: A Retrospective Observational Study.Diagnostics (Basel, Switzerland) · 2020Article
- Early Diagnosis of Pancreatic Cancer: The Key for Survival.Diagnostics (Basel, Switzerland) · 2020Review
- Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management.World journal of gastroenterology · 2020Review
- Role of non-coding RNA in pancreatic cancer.Oncology letters · 2019Review
- Review
- Long non-coding RNA and extracellular matrix: the hidden players in cancer-stroma cross-talk.Non-coding RNA research · 2018Review
- Multilayered heterogeneity as an intrinsic hallmark of neuroendocrine tumors.Reviews in endocrine & metabolic disorders · 2018Review
- Profiling of metastatic small intestine neuroendocrine tumors reveals characteristic miRNAs detectable in plasma.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is well documented that dysregulation of microRNAs is a hallmark of human cancers. Thus, this family of small non-coding regulatory molecules represents an excellent source of sensitive biomarkers. Unique microRNAs expression profiles have been associated with different types and subsets of gastrointestinal tumors including gastroenteropancreatic neuroendocrine tumors (GEP-NETs). GEP-NETs are a heterogeneous group of epithelial neoplasms with neuroendocrine differentiation. At present, early detection and surgical resection of GEP-NETs represent the best chance for a cure. Thus, clinically useful biomarkers for GEP-NETs that strongly correlate with early detection are urgently needed. The purpose of this review is to summarize the role of miRNAs in GEP-NET carcinogenesis and their possible use as novel diagnostic, prognostic and predictive biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.